A France-based KOL provides insights into the treatment paradigm of HER2+ breast cancer with a focus on the reimbursement issues surrounding prescribing drugs for early-stage patients. The KOL also discusses late-phase pipeline drugs being investigated as maintenance therapies, and the impacts of these drugs on later lines of treatment. 

This interview was conducted on Aug. 21, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.